Astrotech Corporation — Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2012. Although the request metadata specifies “2011 Q4,” this filing reports the full fiscal 2012 year; the supplied text does not provide standalone fourth-quarter results. Amounts below are in U.S. dollars unless stated otherwise.
Business context
Astrotech provides satellite and payload processing, launch support, facilities, and related equipment through Astrotech Space Operations (ASO). Its Spacetech unit includes 1st Detect, which launched a miniature mass spectrometer in March 2012, and Astrogenetix, which is pursuing vaccine research. ASO generated 99% of consolidated revenue, leaving the company heavily dependent on its core launch-services business.
Financial performance and liquidity
| Metric | FY2012 | FY2011 |
|---|---|---|
| Revenue | $26.138 million | $20.149 million |
| Gross profit / gross margin | $7.348 million / 28% | $6.481 million / 32% |
| Operating loss | $2.290 million | $5.755 million |
| Net loss attributable to Astrotech | $2.713 million; $0.15 per share | $4.983 million; $0.28 per share |
| Cash from (used in) operations | $(4.109) million | $9.234 million |
| Cash and cash equivalents at year-end | $10.177 million | $14.994 million |
| Working capital | $4.820 million | $5.020 million |
| Total assets | $50.049 million | $57.620 million |
| Debt at year-end | $6.414 million | $6.770 million |
Revenue rose about 30%, primarily from fabrication of ground support equipment (GSE) for the U.S. Government. Gross margin declined as costs of revenue rose nearly as much as revenue. SG&A and R&D fell, contributing to a narrower operating loss. The company reported no annual profit and cash flow from operations turned negative, principally reflecting lower GSE-related deferred-revenue collections and payment timing.
The company had a $6.4 million bank term loan, secured by ASO assets, bearing interest at prime plus 0.25% subject to a 4% floor and maturing in October 2015. No revolving-credit balance was outstanding; the $3 million facility was scheduled to expire in October 2012. Astrotech stated it was covenant-compliant at June 30, 2012 and believed liquidity and backlog would fund at least the next fiscal year. Contractual obligations totaled $7.179 million, including debt and operating leases.
Material changes and unusual items
- ASO revenue increased to $25.817 million from $19.817 million; Spacetech revenue was $0.321 million versus $0.332 million.
- Operating cash flow swung from $9.234 million provided to $4.109 million used. Deferred revenue fell by $8.357 million during FY2012, largely associated with the GSE project.
- Astrotech fully reserved a $0.675 million note receivable due December 2012 after the borrower indicated repayment depended on selling the facility securing the note. This increased interest and other expense.
- The company recorded a $0.2 million non-cash impairment on two historical SPACEHAB modules following the Shuttle program’s retirement.
- Research and development expense decreased to $2.571 million from $3.834 million, including a shift in investment from Astrogenetix to 1st Detect.
- Backlog was $32.274 million, comprising $23.066 million of ASO mission backlog, $9.075 million of ASO facility programs, and $0.133 million of Spacetech grants. It includes scheduled but uncommitted missions and is subject to customer termination.
Outlook, commentary, and risks
No formal quantitative revenue or earnings guidance is provided. Management said it expected to use existing cash and operating proceeds to develop ASO and support Spacetech, and believed liquidity and backlog were sufficient for at least the next fiscal year. The MMS-1000 product launch, government awards, and a NASA agreement for at least 28 additional space flights were described as development opportunities, not assured commercial returns.
- Customer and government concentration is material: about 68% of FY2012 revenue came from NASA and U.S. Government contracts or subcontracts. Revenue and cash flow also depend on launch schedules, which can shift substantially between quarters.
- ASO primarily uses fixed-price contracts, exposing margins to cost overruns and facility-utilization shortfalls. GSE fabrication drove much of the year’s revenue increase.
- Spacetech has limited commercial revenue, operating losses, substantial development and funding needs, and product, regulatory, intellectual-property, and market-acceptance risks. Additional equity funding could dilute shareholders.
- Astrotech cited risks from contract cancellations, government funding uncertainty, competition, access to space, regulatory compliance, audits, and natural disasters affecting Florida and California facilities.
- The Vandenberg land lease was due to expire in July 2013, subject to extension with the lessor’s concurrence. The company also elected not to renew its Cape Canaveral facility lease after December 2012.
- After year-end, CFO John Porter was terminated on August 3, 2012, and Carlisle Kirkpatrick was appointed CFO effective August 9, 2012.
Ernst & Young issued an unqualified opinion on the financial statements. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor did not attest to internal control effectiveness.
Most important facts for investors to verify
- Whether the $32.3 million backlog converts to revenue, particularly the scheduled but uncommitted missions, and whether the GSE program continues to support ASO results.
- Cash burn, deferred-revenue collections, and liquidity after the revolving-credit facility’s October 2012 expiration; confirm subsequent financing and covenant status.
- Collection or recovery prospects for the fully reserved $0.675 million note receivable and any resulting loss or recovery.
- Whether ASO gross margins recover despite fixed-price contract exposure and launch timing variability.
- Commercial sales, funding requirements, and development milestones for 1st Detect and Astrogenetix, including any dilution or obligations associated with Texas funding.
- Renewal or extension of the Vandenberg lease and the operational impact of leaving the Cape Canaveral leased facility.